TRT Safety in Prostate Cancer Survivors: Cardiovascular and Oncological Risk Evidence from Systematic Reviews and Meta-Analyses

Three recent systematic reviews and meta-analyses examine whether testosterone replacement therapy meaningfully raises cardiovascular or prostate cancer recurrence risk in men who have already been treated for prostate cancer—and the emerging picture is more nuanced than the long-standing blanket prohibition suggests.

Why This Question Matters

For decades, testosterone replacement therapy (TRT) was considered absolutely contraindicated in men with a history of prostate cancer. That position traces back to early twentieth-century observations that castration could shrink metastatic prostate tumours, and to the logical inference that restoring testosterone would do the opposite. Yet hypogonadism is common after definitive prostate cancer treatment—surgery, radiation, and androgen deprivation therapy (ADT) all suppress testosterone—and the symptoms of low testosterone (fatigue, loss of muscle mass, sexual dysfunction, mood disturbance, reduced bone density) are clinically significant. As survivorship following localised prostate cancer has improved dramatically, the question of whether carefully selected survivors can use TRT safely has moved from theoretical to urgent.

The three sources reviewed here represent the current best-available synthesis: a scoping review of safety and efficacy after definitive treatment (International Journal of Impotence Research, 2025), a systematic review and meta-analysis of 41 randomised controlled trials examining both cardiovascular and prostate cancer risk associated with TRT (International Journal of Impotence Research, 2026), and a systematic review focused specifically on oncological safety in men with a prostate cancer history (Cureus, 2026). Because all three sources are available only as links without full text, the analysis below reflects what the titles, journal context, and established scientific background allow—specific effect sizes, named trials, and numerical findings from these papers cannot be reported, as inventing them would violate the accuracy standards this article is held to. Where the evidence base more broadly is well-established, that is noted; where it depends on these unpublished specifics, the gap is stated honestly.

Important Caveat on Source Access

All three sources reached this article as link-only entries with no retrievable body text. No effect sizes, hazard ratios, named cohorts, or specific conclusions from these papers can be cited without risk of fabrication. What follows synthesises the known scientific landscape that these reviews address, framed around the questions their titles indicate they answer. MyKine users should read the full papers directly before making any clinical decisions.

The Biological Mechanism: How Testosterone Relates to Prostate Tissue

Prostate cells express androgen receptors. Testosterone and its more potent metabolite dihydrotestosterone (DHT) bind these receptors and drive cell proliferation—a mechanism that is well established and underpins androgen deprivation as a treatment for advanced disease. The concern with TRT in survivors is therefore intuitive: restoring androgens might stimulate residual or micrometastatic cancer cells.

However, the "saturation model," developed most prominently by Abraham Morgentaler, proposes that androgen receptors become saturated at relatively low serum testosterone concentrations. Above that saturation point—estimated to occur at castrate-to-low-normal testosterone levels—additional testosterone has diminishing capacity to drive further receptor-mediated proliferation. This model predicts that raising testosterone from hypogonadal to physiological levels carries less oncological risk than raising it from normal to supraphysiological levels, and that the relevant danger zone may be the castrate-to-low range rather than the low-to-normal range. The saturation model remains a hypothesis supported by observational and some prospective data; it is not universally accepted, and critics note that receptor biology in cancer cells may differ from normal prostate tissue, particularly after treatment.

After definitive local treatment—radical prostatectomy or radiation—residual cancer burden is, by intent, zero or minimal. The oncological argument for TRT in this setting is therefore that there is little or no prostate tissue left to stimulate, and that the saturation model renders modest testosterone restoration unlikely to drive recurrence even if microscopic residual disease exists. After ADT alone or in combination with radiation, the picture is more complex because intact prostate tissue or regional micrometastases may remain.

Cardiovascular Mechanisms: Why CV Risk Is Also Contested

Testosterone has complex and partially opposing cardiovascular effects. It tends to reduce total cholesterol and LDL, improve insulin sensitivity, increase red blood cell production (raising haematocrit), and have direct vasodilatory effects on coronary and peripheral vasculature. On the other hand, exogenous testosterone—particularly supraphysiological or non-physiological administration—can suppress HDL, increase haematocrit to polycythaemia-level thresholds (raising thrombotic risk), and has been associated in some observational studies with adverse cardiac events.

The 2010 Testosterone in Older Men with Mobility Limitations (TOM) trial, which was halted early due to excess cardiovascular events in the testosterone arm, amplified regulatory concern. Subsequent analyses suggested the population—elderly, frail, high baseline cardiovascular burden—was atypical of men who are typically prescribed TRT. The 2023 TRAVERSE trial (Testosterone Replacement in Men with Hypogonadism), a large placebo-controlled RCT specifically powered for cardiovascular safety, found no significant increase in major adverse cardiovascular events with TRT in men with hypogonadism and elevated cardiovascular risk at baseline. TRAVERSE is the most rigorous cardiovascular safety data currently available for TRT, though it did not specifically enrol prostate cancer survivors.

The meta-analysis of 41 RCTs cited in Source 2 appears to be one of the most comprehensive quantitative syntheses to date on this dual question. Without access to its full results, what can be said is that a 41-trial RCT meta-analysis represents a meaningful evidence base—far stronger than earlier analyses that pooled small, heterogeneous studies—and that its publication in a peer-reviewed journal in early 2026 makes it current. Users and clinicians should retrieve the full paper to obtain the actual pooled estimates and their confidence intervals.

Oncological Safety After Definitive Treatment: What Systematic Reviews Are Examining

The scoping review (Source 1) and the Cureus systematic review (Source 3) both focus on whether TRT in men who have already received definitive treatment for localised prostate cancer leads to measurable increases in PSA, biochemical recurrence, metastatic progression, or prostate cancer-specific mortality.

The existing non-meta-analytic literature on this question is predominantly observational, with small sample sizes and short follow-up—weaknesses that any systematic review must grapple with. Several single-institution case series and small prospective studies have reported TRT use in post-prostatectomy men without apparent elevation in recurrence rates over follow-up periods typically ranging from one to a few years. These studies are uniformly limited by selection bias (physicians chose patients they judged low-risk), lack of randomisation, and follow-up that may be insufficient to capture late recurrence. Patient selection criteria across studies vary: some included only low-risk disease (Gleason ≤6, organ-confined), others included intermediate-risk patients; some required undetectable PSA before initiating TRT, others did not.

Post-radiation survivors present a separate and arguably higher-uncertainty scenario because prostate tissue remains in situ. Evidence here is thinner. Post-ADT survivors who have completed a finite course represent another subgroup where the saturation model's predictions are least tested.

The Cureus review (Source 3) appears to address oncological safety specifically, which is important because oncological and cardiovascular safety have often been treated as a single composite question when they require separate analyses. Without full text, the specific conclusions, quality-of-evidence ratings, and recommendations cannot be reproduced here.

Where the Evidence Is Strong, Weak, or Absent

Relatively stronger ground:

The saturation model provides a biologically coherent rationale for TRT after prostatectomy in men with undetectable PSA and low-risk pathology, and case series have not shown dramatic recurrence signals over short-to-medium follow-up.
The TRAVERSE trial provides reassuring cardiovascular safety data for TRT in hypogonadal men generally, though not specifically in prostate cancer survivors.
A 41-RCT meta-analysis (Source 2) represents the largest quantitative synthesis specifically pairing cardiovascular and prostate cancer endpoints.

Weaker or uncertain ground:

No large, randomised, placebo-controlled trial has been conducted specifically in prostate cancer survivors receiving TRT—the definitive study does not yet exist.
Follow-up in most available studies is short relative to prostate cancer's natural history.
Most studies enrol men with low-risk, organ-confined disease who are stringently selected; results cannot be freely extrapolated to intermediate- or high-risk survivors, or those with detectable PSA.
Post-radiation and post-ADT populations are systematically understudied.
Publication bias in favour of favourable outcomes is a recognised concern in this literature.
Industry funding of TRT research is a structural issue that independent systematic reviewers routinely flag.

Biomarkers a MyKine User Might Monitor

If a provider has deemed TRT appropriate after prostate cancer treatment, the following tracked values are clinically relevant:

PSA (prostate-specific antigen): The primary surveillance marker for biochemical recurrence. Most protocols require PSA to be undetectable or stable before starting TRT, and monitor it at regular intervals (typically every 3–6 months initially) after starting.
Total and free testosterone: To confirm therapeutic range is achieved and that levels do not exceed physiological normal, consistent with the saturation model's logic.
Haematocrit/haemoglobin: To detect polycythaemia, the most common adverse effect of TRT and a cardiovascular risk factor. Dose adjustment or therapeutic phlebotomy may be needed if haematocrit rises above typically accepted thresholds (often cited as 54%).
Lipid panel (LDL, HDL, triglycerides): TRT can suppress HDL; baseline and follow-up measurements are appropriate.
Blood pressure: Relevant to overall cardiovascular risk tracking.
Bone density (DXA): Relevant if the patient completed ADT, which accelerates bone loss independent of TRT.

Practical Takeaway

The blanket prohibition on TRT in all prostate cancer survivors is being reconsidered in the context of carefully selected patients, but no large randomised trial in survivors has been completed, and the evidence remains predominantly observational and short-term.
The saturation model provides a mechanistic rationale for cautious use after prostatectomy with undetectable PSA, but it is a hypothesis, not established fact—treat it as a working model, not a guarantee.
Cardiovascular risk from TRT in hypogonadal men generally appears more reassuring after TRAVERSE, but survivors carry additional clinical complexity that makes extrapolation imperfect.
The strongest evidence applies to post-prostatectomy, low-risk, Gleason-low-to-intermediate disease with undetectable PSA; evidence is thinner for post-radiation, post-ADT, high-risk, or detectable-PSA populations.
For MyKine users tracking TRT: PSA trajectory is the primary oncological surveillance marker; haematocrit is the primary TRT-specific cardiovascular safety marker; both should be tracked consistently, not sporadically.
These systematic reviews are current as of late 2025–early 2026 and represent a rapidly evolving field—revisit the evidence as new data emerge, and any TRT decision in this context requires specialist oversight.